The cardiologists, nurses and technicians of Sacramento’s first transcatheter aortic valve replacement (TAVR) team celebrated a milestone on March 6. For five years, they have provided a minimally invasive treatment option to patients with aortic valve stenosis.
The disease, which previously could only be treated with surgery, reduces blood flow from the heart through the aortic valve due to calcification, a prior infection or a birth defect. TAVR replaces the diseased valve with a new one entirely with catheters threaded through arteries. (Watch the video about the process on UC Davis Health's YouTube channel.)
TAVR was at first only available to high-risk surgery patients. Today, the procedure is also approved for intermediate-risk surgical patients.
“Prior to TAVR, patients with aortic valve stenosis who could not have surgery had very few options,” said Jeff Southard, associate professor of cardiovascular medicine. “The TAVR program is a perfect example of UC Davis’ national leadership in providing cardiology patients with the newest, most effective and safest treatments as soon as possible.”
For information about TAVR at UC Davis, call 916-734-6500.
Cardiovascular medicine at UC Davis Health unites specialists and subspecialists who are passionate about providing the highest level of care for cardiac and blood-vessel disease. In addition to being compassionate clinicians, they are national leaders in developing and testing the next generation of cardiac and vascular therapies, technologies and surgical techniques, and then making them available to patients worldwide. For information, visit heart.ucdavis.edu.